1. Omalizumab effectively protects against early and late allergic responses in asthma after 4 weeks. Issue 12 (28th June 2017) Authors: Trischler, J.; Lieb, A.; Arnold, M.; Schulze, J.; Rosewich, M.; Schubert, R.; Bottoli, I.; Zielen, S. Journal: Allergy Issue: Volume 72:Issue 12(2017:Dec.) Page Start: 1912 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects. Issue 11 (November 2014) Authors: Arm, J. P.; Bottoli, I.; Skerjanec, A.; Floch, D.; Groenewegen, A.; Maahs, S.; Owen, C. E.; Jones, I.; Lowe, P. J. Journal: Clinical & experimental allergy Issue: Volume 44:Issue 11(2014:Nov.) Page Start: 1371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗